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Summary
Despite recent advances in treatment that have significantly
improved overall survival, multiple myeloma (MM) remains
incurable. Although rituximab, the first monoclonal antibody
(MAb) evaluated in MM treatment, provided only very limited
benefit, research is ongoing into a number of other MAbs
directed against a variety of MM-related target antigens. Given
the inherent immune dysfunction associated with MM, newer
strategies that may enhance immune function in conjunction
with antibodies may also provide a more fruitful clinical
approach. Potential MAb targets in MM include growth
factors and their receptors, other signalling molecules, and
antigens expressed exclusively or predominantly on MM cells.
MAb therapy involves a range of mechanisms, including
antibody-dependent cellular cytotoxicity, complement-depen-
dent cytotoxicity, interference with receptor-ligand interac-
tions, and MAb conjugation to radioisotopes or toxins. The
antigens currently targeted in MM therapy are discussed, along
with the development status of the corresponding MAb
therapeutics. Elotuzumab, an anti-CS1 MAb, has recently
achieved clinically meaningful responses when combined with
lenalidomide or bortezomib in patients with relapsed and
relapsed/refractory MM. Other MAbs are also showing early
promise. More ongoing clinical research is required to identify
optimal combination regimens and biomarkers that may help
predict response to specific MAb-based combinations.
Keywords: multiple myeloma, monoclonal antibodies, novel
therapies, novel targets, targeted therapies.
Multiple myeloma (MM) is a malignancy of plasma cells and
represents about 15% of newly-diagnosed haematological
cancers in the USA; specifically, about 20 000 new MM cases
are diagnosed each year, with MM accounting for more than
10 000 fatalities annually (Jemal et al, 2010). Prior to the
introduction of chemotherapy using the alkylating agent
melphalan (in combination with prednisone) in the early
1960s, median survival in MM was <1 year after diagnosis;
melphalan-prednisone combination therapy improved the
median survival to 2–3 years at best (Kumar et al, 2008; San
Miguel et al, 2008). Since then, clinical advances in MM
therapy have included the use of high-dose chemotherapy
supported by autologous stem cell transplantation (ASCT) in
the mid-1990s; the development of bisphosphonates for the
treatment of MM-related bone disease; the introduction of
thalidomide as MM therapy in the late 1990s; the approval of
the first-in-class proteasome inhibitor bortezomib in 2003; and
the later introduction of the second generation immunomod-
ulatory drug (IMiD) lenalidomide in 2005 (Kumar et al,
2008; Mhaskar et al, 2010).
These therapeutic advances, particularly the introduction of
bortezomib, thalidomide, and lenalidomide, have led to clin-
ically significant increases in overall survival (OS). For example,
a retrospective study of 2981 Mayo Clinic patients showed that
median OS from date of diagnosis was 29Æ9 months [95%
confidence interval (CI) 28Æ3–31Æ6 months] for patients diag-
nosed prior to December 1996, compared with 44Æ8 months
(95% CI 39Æ6–50Æ0 months) for those diagnosed between
January 1997 and December 2006 (Fig 1) (Kumar et al, 2008).
The observed gains in OS were achieved primarily by
younger patients: for patients £65 years at diagnosis, median
OS was 60 months for diagnoses between 1997 and 2006 and
33 months for diagnoses prior to 1997; in contrast, for patients
>65 years at diagnosis, median OS was 32 months and
26 months for diagnoses between 1997 and 2006 and prior to
1997, respectively. OS gains were particularly important among
patients who relapsed following ASCT, and these increases are
clearly attributable to the introduction of novel agents, and in
the case of this study predominantly thalidomide and lenalid-
omide (Fig 2). During the past decade, median OS among
patients who received 1 or more of the newer drugs after post-
ASCT relapse was 30Æ9 months (95% CI 23Æ6–38Æ2 months),
compared to 14Æ8 months (95% CI 11Æ3–18Æ4 months) for
those who did not (P < 0Æ001) (Kumar et al, 2008).
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A similar pattern of improvements in OS was observed in a
Swedish study of MM therapy, in which patients were stratified
by date of diagnosis and age at diagnosis (Kristinsson et al,
2007). Across all age groups, 1-year survival improved
significantly among patients diagnosed during 1994–2003
compared with those diagnosed during 1973–1979 and 1980–
1986. However, as with the Mayo Clinic study, significant
improvements in 5-year and 10-year survival were confined to
patients younger than 60 years and 70 years at diagnosis,
respectively.
Despite these documented improvements in OS, MM
remains incurable in the vast majority of patients. Although
MM has become a more treatable disease, the development of
resistant/refractory disease is inevitable, and leads to death.
Thus, an urgent need remains for therapies that can further
extend disease control, potentially achieving longer term
remission in patients with MM, and ideally without the
addition of significant treatment-related toxicities.
In addition to the established use of thalidomide, lenalid-
omide, and bortezomib-based combination therapies (Rich-
ardson et al, 2007), a number of new targeted agents,
developed on the basis of disease biology, are being pursued
both as monotherapy and in combination with established
treatment options (Table I). These include second generation
proteasome inhibitors (such as carfilzomib) and third gener-
ation immunomodulatory drugs (specifically pomalidomide)
(Jagannath et al, 2010); inhibitors of histone deacetylase
(vorinostat, panobinostat, romidepsin), heat shock protein
90 (tanespimycin), Akt (perifosine), and kinesin spindle
protein (KSP; ARRY-520) (Jagannath et al, 2010; Shah et al,
2010; Niesvizky et al, 2011); enhancers of natural immune
surveillance using vaccination or dendritic cell infusion
(Rosenblatt et al, 2011); and a range of monoclonal antibodies
(MAb) directed at mediators of MM cell survival, tumour
progression, and interactions with the bone marrow (BM)
microenvironment.
This review focuses on the role of MAb therapy in MM,
describing potential targets and agents currently in develop-
ment. We examine targets and MAbs that have demonstrated a
high level of cytotoxicity/efficacy against MM in preclinical
and clinical studies.
Monoclonal antibody therapy in multiple
myeloma
General considerations
A wide range of antigens may ultimately be targeted in MM
therapy, including those involved in cell survival, anti-apop-
totic pathways, cell-to-cell communication, angiogenesis, and
interactions between MM cells and bone marrow stromal cells
(BMSCs) and/or other cells in the BM microenvironment
(Kastritis et al, 2009; Di Bernardo et al, 2010). These potential
targets include signalling molecules, cell surface receptors and
other cell surface proteins, plasma cell growth factors, and
mediators of adhesion. Ideally, a useful target for MAb-based
MM therapy should be expressed exclusively on a majority of
MM cells (or other target cells such as those involved in
angiogenesis), or to a much higher level than on non-target
cells (Di Bernardo et al, 2010).
Effective MAb-based MM therapy may involve a number of
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Fig 2. Improvements in multiple myeloma overall survival following
relapse after autologous stem cell transplantation.Source: Blood by
American Society of Hematology. Copyright 2008 Reproduced with
permission of American Society of Hematology (ASH) in the format
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Fig 1. Improvements in multiple myeloma overall survival following
diagnosis, 1971–2006.Source: Blood by American Society of Hematol-
ogy. Copyright 2008 Reproduced with permission of American Society
of Hematology (ASH) in the format Journal via Copyright Clearance
Center.
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interference with cell-cell interactions. The most commonly
observed cytotoxic mechanisms in preclinical and early clinical
studies are antibody-dependent cellular cytotoxicity (ADCC)
and complement-dependent cytotoxicity (CDC). Other possi-
ble mechanisms include interference with ligand binding (e.g.
growth factor or G-protein coupled receptors) and the use of
MAbs as targeted ‘carriers’ of cytotoxic agents. The latter
mechanism may be especially useful as a way of conveying
intracellular toxins (in the case of MAbs that are internalized)
or radioactive isotopes, which may have cytotoxic effects that
extend beyond cells bearing specific MAb targets (Weiner et al,
2010).
Rituximab in MM
The earliest evaluations of MAb therapy targeting MM were
based on the success of rituximab, an antibody to the B-cell
specific antigen CD20, in the treatment of lymphoma.
Rituximab was the first MAb approved for any cancer therapy,
and is currently indicated for treatment of chronic lympho-
cytic leukaemia and non-Hodgkin lymphoma (http://www.
gene.com/gene/products/information/pdf/rituxan-prescribing.
pdf). Rituximab exhibits impressive activity in these disease
states, especially in combination with cytotoxic chemotherapy
and as maintenance therapy (Kapoor et al, 2008; Salles et al,
2011).
However, clinical studies of rituximab therapy in MM have
generally been disappointing, with few patients achieving only
minimal responses (MR) (Kapoor et al, 2008). The failure of
rituximab in this setting is potentially attributable to the small
number of MM patients (estimated at 13–22%) who express
CD20 in primarily a low proportion of plasma cells. Another
mechanism that may render MM refractory to rituximab is the
possibility that MM cells express increased levels of comple-
ment-inhibiting proteins, reducing the effectiveness of CDC.
In addition, Fc-c receptor polymorphism may limit the
effectiveness of ADCC as a killing mechanism. Finally, the
use of rituximab in MM may induce a selective loss of CD20
expression.(Kapoor et al, 2008) Although it is conceivable that
rituximab may be useful in certain carefully-selected MM
patients, such as t(11;14) translocation patients, who exhibit
relatively high CD20 expression (Robillard et al, 2003), it is
unlikely to be of value in the majority of MM cases.
Novel targets and MAbs in development
A number of other potential antigen targets are being
investigated in the context of MM therapy, and several have
reached clinical trials. Some of the most promising MM-
related antigen targets are described here, along with the
corresponding MAb therapeutics in development (Table II).
Interleukin-6 (IL-6). IL-6 has been recognized as a key
cytokine in the development and progression of MM,
exerting anti-apoptotic activity and multiple additional
effects within the BM. IL-6 is produced predominantly by
BMSCs, and is upregulated by multiple cytokines (Kastritis
et al, 2009). Both IL-6 and its receptor, IL-6R, are potential
targets for MAb-based intervention.
A chimeric anti-IL-6 MAb, siltuximab (CNTO 328),
enhances dexamethasone-induced cytotoxicity in MM cell
lines and in MM cells from patients refractory to dexameth-
asone therapy; it also enhances the cytotoxicity of the
bortezomib plus dexamethasone combination (Trikha et al,
2003; Voorhees et al, 2009). Siltuximab has demonstrated
activity in the lymphoproliferative disorder Castleman’s
disease (van Rhee et al, 2010), and is currently being
evaluated in MM in multiple single-arm and randomized
Table I. Selected novel therapies in development for treatment of multiple myeloma (excluding monoclonal antibodies).
Name (Brand name) Developer Type Status* Regimen
Carfilzomib Onyx Pharmaceuticals, San
Francisco, CA, USA
Proteasome Inhibitor Phase 3 enrolling + lenalidomide + dexamethasone
Pomalidomide Celgene Corporation, Summit,
NJ, USA
IMiD Phase 3 enrolling Monotherapy
+ dexamethasone
Vorinostat (Zolinza) Merck & Co., Inc., Whitehouse
Station, NJ, USA
HDAC inhibitor Phase 3 ongoing + bortezomib
Panobinostat Novartis Oncology, East
Hanover, NJ, USA
HDAC inhibitor Phase 3 enrolling + bortezomib + dexamethasone
Romidepsin Celgene Corporation HDAC inhibitor Phase 2 ongoing Monotherapy
+ bortezomib
Perifosine Keryx Biopharmaceuticals, New
York, NY, USA
Akt inhibitor Phase 3 ongoing + bortezomib + dexamethasone
Arry-520 Array Biopharma, Boulder, CO,
USA
KSP inhibitor Phase 1/2 enrolling Monotherapy
Phase 1 enrolling + bortezomib + dexamethasone
HDAC, histone deacetylase; Hsp, heat shock protein; IMiD, immunomodulatory drug; KSP, kinesin spindle protein.
*In most advanced clinical trial(s).
Review






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































748 ª 2011 Blackwell Publishing Ltd, British Journal of Haematology, 154, 745–754
Phase 2 studies, either alone or in combination with
bortezomib (NCT01219010, NCT00402181, NCT00911859,
NCT00412321, NCT00401843). Preliminary results in combi-
nation with bortezomib have shown promise, with a 57%
objective response rate (ORR), although grade 3+ haemato-
logical toxicities were somewhat common (Rossi et al, 2008).
A Phase 3 study of siltuximab or placebo in combination with
bortezomib and dexamethasone is underway (NCT01266811).
A murine anti-IL-6 MAb, BE-8, has been evaluated in
combination with dexamethasone and high-dose melphalan as
a conditioning regimen for ASCT; the combination induced a
response in 13 of 16 patients (81%) and a complete response
(CR) in 6 patients (37Æ5%). The overall response (OR) was
similar to historical controls by the same group of high-dose
melphalan; however, the CR rate appeared to be higher, and
was correlated with IL-6 neutralization (Moreau et al, 2000).
In a subsequent prospective, multicentre randomized trial by
the same group, the addition of BE-8 to the melphalan plus
dexamethasone conditioning regimen showed no improve-
ment in response or survival rates for patients with high-risk
MM (Moreau, et al 2006).
Tocilizumab is a humanized anti-IL-6 MAb currently
approved for rheumatoid arthritis in several countries and
for Castleman disease in Japan. Tocilizumab has demonstrated
efficacy in a murine MM model (Yoshio-Hoshino et al, 2007)
and is currently being evaluated clinically in MM. Another
anti-IL-6 MAb, 1339, has demonstrated activity on MM cell
lines (co-cultured with BMSCs) in vitro, and in murine
xenograft MM models; it is not yet being evaluated clinically
(Fulciniti et al, 2009a).
Vascular endothelial growth factor (VEGF). VEGF is a key
cytokine that promotes angiogenesis in a variety of tumour
types, facilitating improved blood flow that is critical to
tumour cell survival (Veikkola et al, 2000). Bevacizumab, a
humanized anti-VEGF MAb, is currently indicated for
treatment of colorectal cancer (http://www.gene.com/gene/
products/information/pdf/avastin-prescribing.pdf). In a Phase
2 study in patients with relapsed/refractory MM, seven of 10
patients responded [partial response (PR)] to bevacizumab in
combination with low-dose dexamethasone and lenalidomide
(Raschko et al, 2007). An additional Phase 2 study of the same
combination reported similar results in a larger patient
population (OR 19/27, 70%) (Callander et al, 2009), noting
that this response rate was not significantly different from that
seen in the pivotal Phase 3 trial of lenalidomide plus
dexamethasone (61%) (Weber et al, 2007). An additional
Phase 2 study of this combination is currently recruiting
patients (NCT00410605) and the drug is also being evaluated
in combination with bortezomib (NCT00464178,
NCT00473590).
CD40. CD40 is a member of the tumour necrosis factor
(TNF) receptor superfamily that is highly expressed on MM
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CD40 by its ligand (CD40L) induces a range of biological
effects, including MM cell proliferation and migration,
mediated primarily via the PI3K/AKT pathway, and
induction of VEGF overexpression. VEGF overexpression is
especially pronounced in MM cells with mutated TP53, and
VEGF also stimulates production of IL-6 by BMSCs (Tai et al,
2002, 2003).
Two anti-CD40 antibodies, dacetuzumab (SGN-40) and
lucatumumab (CHIR-12Æ12, HCD122), have been evaluated in
preclinical studies. SGN-40 is a humanized anti-CD40 MAb
that induces cell death and/or growth arrest in MM cell lines;
among other effects, dacetuzumab down-regulates IL-6R,
rendering cell lines unresponsive to IL-6 stimulation (Tai
et al, 2004). Cell line studies and a Phase 1 monotherapy study
have shown that the primary cytotoxic mechanisms appear to
be induction of apoptosis (potentially related to IL-6R
suppression) and ADCC (Hayashi et al, 2003; Tai et al,
2004). The observation that SGN-40-induced MM cell death
is enhanced by lenalidomide (Tai et al, 2005a) led to its
evaluation in a Phase 1 study in combination with lenalido-
mide and dexamethasone in patients with relapsed or refrac-
tory MM; an OR of 39% (13/36) was seen, with some activity
noted in patients receiving prior lenalidomide (Agura et al,
2009).
Lucatumumab is a fully human anti-CD40 MAb that
inhibits MM cell growth in vitro, even when MM cells are
cocultured with BMSCs. Animal studies have shown that the
primary cytotoxic mechanism is ADCC (Tai et al, 2005b).
Lucatumumab has been found to inhibit multiple pathways
that are induced by CD40L binding to CD40, including AKT
phosphorylation and signalling and MM cell adhesion to
BMSCs and to fibronectin, in addition to suppression of IL-6
and VEGF (Tai et al, 2005b). However, a Phase 1 study of
lucatumumab in patients with relapsed/refractory MM was
terminated because of minimal biological and clinical activity
(NCT00231166).
CD74. CD74 is a transmembrane protein that forms the
invariant portion of HLA-DR; it is expressed on MM cells in a
majority of patients. Because CD74 exists in a dynamic pool
and is rapidly internalized, an anti-CD74 antibody might be
useful as a carrier for cytotoxins (Burton et al, 2004). This
approach is being employed with milatuzumab (hLL1), a
humanized anti-CD74 MAb coupled with the anthracycline
doxorubicin to form a conjugated antibody designated
IMMU-110 (Sapra et al, 2005). In cell line and mouse
xenograft experiments, IMMU-110 demonstrated high
activity against MM, and it also appeared to be safe in a
monkey model of MM (Sapra et al, 2005). IMMU-110 is being
evaluated in a Phase 1/2 study (NCT00421525), and a Phase 2
study is currently ongoing (NCT01101594).
CD56. CD56 (neural cell adhesion molecule, NCAM) is
expressed on neurons, muscle cells, and a variety of tumours,
including MM; it appears to mediate cell adhesion, migration,
and invasion (Mechtersheimer et al, 1992; Lutz & Whiteman,
2009). Lorvotuzumab mertansine (IMGN901), an
immunoconjugate composed of a humanized MAb to CD56
(huN901) conjugated to the maytansinoid DM1, has shown
activity against MM cell lines (Tassone et al, 2004a; Lutz &
Whiteman, 2009). Two Phase 1 studies (one as monotherapy,
one in combination with lenalidomide and dexamethasone)
are currently recruiting patients (NCT00346255,
NCT00991562).
CD38. CD38 is a glycoprotein found on the surface of many
immune system cells, including MM cells (Stevenson, 2006). A
human anti-CD38 MAb, HuMax-CD38, has demonstrated
preclinical activity against MM cell lines and patient-derived
MM cells, with cytotoxic effects that involve both ADCC and
CDC (Stevenson, 2006). HuMax-CD38 is being evaluated in a
Phase 1/2 safety study in patients with relapsed or refractory
MM that is currently recruiting participants (NCT00574288).
Results of this preliminary study are awaited with interest, with
early reports suggesting favourable tolerability and disease
stabilization in some patients.
CD138 (Syndecan-1). CD138 is a cell surface heparin sulphate
proteoglycan, highly expressed on plasma cells and MM cells,
that is involved in cell adhesion and maturation (Tassone et al,
2004a; Ikeda et al, 2009). Two different MAbs conjugated to
cytotoxic maytansinoid derivatives (which disrupt microtubule
assembly) have been evaluated in preclinical studies. B-B4 is a
murine MAb against CD138 that has been conjugated to the
maytansinoid DM1; it is cytotoxic in vitro to MM lines, and to
MM lines and patient-derived MM cells in mouse xenograft
models (Tassone et al, 2004b). BT062 is a chimeric MAb
conjugated to maytansinoid derivatives that demonstrates in
vitro cytotoxicity and inhibition of MM cells in mouse
xenograft models, apparently via apoptotic mechanisms;
BT062 also inhibits the adherence of MM cells to BMSCs
and abrogates the protective effects exerted by growth factors
and BMSCs on MM cells (Ikeda et al, 2009). A Phase 1 dose-
finding study of BT062 for patients with relapsed/refractory
MM is underway (NCT00723359), and an additional Phase 1/
2a study is recruiting patients with advanced MM
(NCT01001442).
GM-2 ganglioside. GM-2 is a ganglioside expressed on MM
cells. A humanized anti-GM-2 MAb, BIW-8962, has
demonstrated in vitro killing of MM cell lines and in vivo
effectiveness in mouse xenograft models, with ADCC and CDC
the most prominent cytotoxic mechanisms (Ishii et al, 2008).
BIW-8962 is being evaluated as monotherapy in a Phase 1/2
study for patients with relapsed/refractory MM
(NCT00775502).
CD200. CD200 is a highly conserved transmembrane
glycoprotein expressed on a wide range of cell types;
however, expression of the receptor for CD200 (CD200R1) is
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apparently limited to antigen-presenting cells of myeloid
lineage and certain T-cell populations, and is thought to
deliver inhibitory signals. The expression of the CD200 gene by
MM cells has been found to be a predictor of poor prognosis in
patients with MM (Moreaux et al, 2006). ALXN6000 is a
humanized anti-CD200 MAb that is currently being evaluated
in a Phase 1/2 study in patients with MM or B-cell CLL
(NCT00648739), with results expected in the near future.
Killer cell immunoglobulin-like receptors (KIR). KIRs are
receptors expressed on natural killer (NK) cells and a
subset of T cells and function as key regulators of NK
cell activity (Campbell & Purdy, 2011). Several studies
are currently underway in smouldering and first relapse
MM (NCT01222286, NCT01217203, NCT00999830,
NCT01248455), and safety and tolerability results are
expected later in 2011 for a Phase 1 study in relapsed or
refractory MM (NCT00552396).
CS1 (CD2 subset 1, CD319, CRACC, SLAMF7, 19A24). CS1
is a cell surface glycoprotein universally expressed at high
levels on MM cells but with limited expression on normal
cells (Hsi et al, 2008; Tai et al, 2008). The function of CS1 is
not well characterized, but it appears to play a critical role in
interactions between MM cells and BMSCs (Tai et al, 2008).
Its expression pattern suggests that it may be an attractive
target for MAb therapy in MM. Elotuzumab (HuLuc63) is a
fully humanized MAb against CS1 that has shown significant
in vitro activity as monotherapy against patient-derived MM
cell lines, and in vivo activity in a mouse MM xenograft
model (Tai et al, 2008). These studies showed that
elotuzumab-induced cell death was mediated primarily via
ADCC, and that elotuzumab was active even in MM cells
refractory to conventional and targeted therapies (Tai et al,
2008).
Elotuzumab has also been evaluated in Phase 1 and Phase 2
clinical studies in patients with relapsed/refractory MM. In a
Phase 1 monotherapy study, elotuzumab demonstrated accept-
able toxicity but its antitumour activity was only modest: no
responses were seen, although elotuzumab did induce stable
disease (SD) in six of 19 patients (Zonder et al, 2008).
Despite the limited activity of elotuzumab monotherapy,
preclinical data suggested that combinations of elotuzumab
with novel agents (specifically bortezomib and lenalidomide)
acted synergistically, enhancing ADCC in both cell line and
xenograft models (Tai et al, 2008; van Rhee et al, 2009).
Clinical studies of elotuzumab combined with either lenalid-
omide plus dexamethasone or with bortezomib were therefore
initiated and are showing considerable promise. In a
preliminary analysis of an ongoing Phase 1 study of elot-
uzumab plus bortezomib, the ORR (PR or better) was 48% of
27 evaluable patients, and responses were achieved in several
bortezomib-refractory patients; a clinical response (‡MR) was
seen in 17/27 (63%) patients. The response rate was lower
among heavily-pretreated patients (‡3 prior therapies) and the
median time to progression was 9Æ46 months (Jakubowiak
et al, 2010).
In a preliminary analysis of an ongoing Phase 1b combina-
tion study with lenalidomide and dexamethasone, the ORR
was 82% for all treated patients (N = 28), 96% for lenalido-
mide-naı̈ve patients (n = 22), and 82% among patients who
had been refractory to their most recent treatment (n = 11)
(Lonial et al, 2010). In a Phase 2 study of the same
combination, the ORR was 85% for evaluable patients (22/
26), and the remaining four patients had SD; 31% achieved
either a CR or very good partial response (Richardson et al,
2010). For both studies, adverse events (AEs) were primarily
infusion-related, and appeared to be readily manageable using
adequate premedication.
Elotuzumab is therefore the first MAb in combination with
either bortezomib or lenalidomide and dexamethasone to
demonstrate clinically meaningful efficacy in relapsed/refrac-
tory MM. It is also an excellent example of rational design of
combination therapies. In particular, given the modest results
observed with monotherapy, further drug development may
have been stopped if it were not for preclinical research
demonstrating synergy in combination with bortezomib or the
lenalidomide/dexamethasone combination. Across all clinical
studies to date, most AEs attributable to elotuzumab included
mild to moderate infusion reactions, and the implementation
of more aggressive premedication regimens appeared to reduce
the rate of infusion-related AEs (Zonder et al, 2008; Lonial
et al, 2010; Richardson et al, 2010).
Monoclonal antibody therapy for myeloma-
related end-organ complications
In addition to therapy directed at MM cells and tumour-
promoting interactions, some efforts have been devoted to
MAb therapy directed against the development of end-organ
complications; to date, these efforts have been restricted to the
suppression of myeloma-related bone disease.
RANK ligand (RANKL)
RANKL promotes bone loss in osteoporosis and contributes to
the development of bone lesions in MM. The inhibition of
RANKL may directly impact myeloma cells that express RANK
and have a therapeutic role in the treatment of MM. The fully
human anti-RANKL MAb, denosumab, has demonstrated
some efficacy in a Phase 2 study of patients with plateau-phase
or relapsed MM, including suppression of the bone turnover
marker serum C-terminal telopeptide of type 1 collagen (sCTx)
(Vij et al, 2009). Denosumab is currently being compared with
zoledronic acid (the standard of care for prevention of bone
disease in several cancers) in patients with advanced cancers or
MM in a randomized Phase 3 trial (NCT00330759); results in
the MM cohort have thus far been mixed although positive in
other cancers; future trials are planned in MM to better define
its role.
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Dickkopf-related protein 1 (DKK1)
DKK1 facilitates the development of bone lesions in MM,
primarily by inhibiting the activity of osteoblasts. A fully
human anti-DKK1 MAb, BHQ880, has demonstrated
improvement in bone parameters in murine models, and also
appears to have direct effects on MM cell growth, possibly via
interactions with BMSCs and IL-6 related pathways (Fulciniti
et al, 2009b; Heath et al, 2009). BHQ880 is being evaluated in
combination with zoledronic acid in a Phase 2 study in
patients with relapsed/refractory MM (NCT00741377), and
studies in early MM (i.e, smouldering MM) are also underway.
The role of monoclonal antibodies in multiple
myeloma management
MM exhibits a number of potentially valuable targets for MAb
therapy that await further investigation in clinical studies. As
has been the case with other cancers, MAbs, when employed as
monotherapy in MM, have generally not produced impressive
levels of response with respect to either response rates or extent
of response in individual patients. However, preclinical results
in MM cell lines and murine explant models, and preliminary
clinical results in patients with relapsed/refractory MM suggest
that MAbs are likely to act synergistically with traditional
therapies (dexamethasone), immune modulators (thalido-
mide, lenalidomide), and other novel therapies (such as the
first-in-class proteasome inhibitor bortezomib); in addition,
MAbs have shown the ability to overcome resistance to these
therapies. These observations suggest that future work may be
most productively directed at the rational development of
multi-agent therapies incorporating specific MAbs on the basis
of clinical trial results and, possibly, on the identification of
patient-specific MM disease factors. To that end, response
assessments in future clinical studies may incorporate biomar-
ker evaluations to identify patient subsets that are most likely
or unlikely to respond to specific MAbs.
The current model for the development and approval of
novel cancer therapies involves a potential paradox, in that
they are initially evaluated in patients with late-stage, meta-
static, relapsed, and/or refractory disease; and only if activity is
shown in these patients relative to existing standards of care
are they likely to be evaluated in the treatment of early-stage
disease. However, advanced malignancies are extremely chal-
lenging therapeutic targets (Rothenberg et al, 2003), involving
extensive genetic heterogeneity and multiple resistance mech-
anisms; while targeted therapies, by definition, are directed
against individual components or pathways (albeit with
potentially pleiotropic effects). Therefore, the activity of novel
targeted therapies (including MAbs) is likely to be greatest
against early-stage disease that possesses far fewer mechanisms
for resistance or escape. Evaluating novel therapies in earlier
stage disease may therefore be beneficial with respect to
identifying potentially useful agents that fail to show measur-
able activity against more advanced disease.
The natural history of MM, now well understood as a
progression from monoclonal gammopathy of undetermined
significance (MGUS) to asymptomatic (smouldering) MM,
and then to symptomatic MM, often with extramedullary
progression in the advanced and late stage setting, may afford
additional targets for MAb therapy. As yet, treatment is not
recommended for MGUS, and options are limited (e.g.
bisphosphonate alone) in smouldering MM, as potential
toxicities may outweigh the potential benefits. Future research
should be directed at further elucidation of the molecular
events involved in progression from MGUS to symptomatic
MM, and the identification of targets that may prevent or
reduce the risk of disease progression, for which MAbs, as an
example and given their favourable side effect profile, may
have a potential role.
Conclusions
MAb therapy for MM remains early in its development. As yet,
it remains to be defined how MAb therapy can most
productively be incorporated into the current therapeutic
paradigms that have achieved significant survival gains in
patients with MM. However, based on preclinical and
preliminary clinical evaluation, as well as MAb therapy
experience in other cancers, it is apparent that MAb therapy
will probably be most effective when combined with existing
MM therapies and, in particular, novel agents. The results of
ongoing and future clinical studies of MAb therapy in MM
should help identify rational combination strategies that
produce improved patient outcome. This should be reflected
both in terms of increased OS and of quality of life, given the
favourable tolerability profile and the remarkable response
rates and durations seen to date.
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